🔗 Share this article

While the US proceeds with unprecedented adjustments to its vaccination schedules, an unexpected name appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by questioning coronavirus shots during the global health crisis and has focused upon possible deaths following Covid vaccination in her brief time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Public health authorities planned to reveal radical revisions to the pediatric immunization program earlier this month, aligning the US with the Danish national calendar, it is understood – a significant shift that would put the US at odds with many the world with little proof for public health gain. The announcement has been pushed back until the coming year.

Rather than the top vaccines chief, Dr. Høeg is set to present at the event. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to lead the office this year.

A Shift at the FDA

The acting appointment may indicate a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a increased emphasis upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing certain childhood immunization guidelines in the US to become more similar to the Danish model, a society with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccination policy – traditionally the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in pharmaceutical research, regulation or leadership, which has been standard for previous heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a large organization. She lacks background in drug approvals.”

Previous directors of the center would “understand legal statutes and the science of drug development”, noted Janet Woodcock. “Clearly, she lacks the type of experience that former directors who ran CBER have had.”

CDER has an immense portfolio at the FDA, the former commissioner pointed out.

“The public just focuses on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There is also a biosimilars division, over-the-counter program and other areas, and all of those must be looked after,” Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial administrative component to the job, which oversees more than 5,000 employees. “It is a enormous administrative position, if you perform it correctly,” she said.

Agency Reaction and Disputed Policies

Regarding concerns about Dr. Høeg's credentials and whether this assignment represents greater collaboration among FDA leaders on vaccines, a spokesperson said that the “questions are based on flawed assumptions”.

“Her resume matches the functions of her position,” the spokesperson stated, pointing to the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's controversial expedited review system, a controversial rapid therapy clearance system that apparently worried her preceding directors. “By what process are these medications being chosen for this expedited pathway? Who makes the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the agency appears to be shifting towards less stringent regulations of most medications, except for shots.”

Documented History on Immunizations

Concerning vaccines, Høeg has a more documented, if concerning, track record, critics observe. She authored a analysis using unverified public submissions to estimate the frequency of myocarditis following COVID-19 immunization. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the new federal leadership included changing guidelines for novel immunizations and discontinuing “unnecessary” vaccines, she stated following the vote on a audio program. At the FDA, Dr. Høeg has allegedly proposed excluding adolescent males from getting COVID-19 vaccines.

“She’s an complete true believer who begins with her preconceived notions and works backwards to retrofit the data in a very disingenuous, untruthful fashion,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|